In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...
Pfizer (NYSE: PFE) is the name behind one of the world's top-selling products: the coronavirus vaccine. It brought in more than $37 billion at its peak in 2022 and helped the company achieve $100 ...
Shares of Pfizer (NYSE: PFE) have fallen 55% from their late 2021 high. That decline highlights a material change in Wall Street's view of the pharmaceutical giant. And it has pushed the dividend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results